About this trial
Cardiovascular disease, type 2 diabetes mellitus and associated diseases combined are the leading health burden and cause of mortality worldwide; therefore, the necessity for an intervention is paramount. Dietary interventions to improve cardiometabolic health are highly sought after as they possess less risk than pharmacological drugs. It has been postulated that Berberine may be beneficial in improving cardiometabolic outcomes. However, to date, no research has explored this using a placebo randomized intervention.
Eligibility criteria
Qualifiers
Healthy
Between 18 & 65 years
Non-smoker
BMI < 30
Disqualifiers
Pregnancy
Diabetes or any other metabolic/ uncontrolled hypertensive conditions
Food allergies to berberine
Habitual consumption of berberine
Trial design
Treatments tested in this trial
- Berberine
- Placebo
Treatment groups
Locations
Sponsors and collaborators
University of Central Lancashire
Lead sponsor
DoNotAge.org
Collaborator